Novo Nordisk A/S: Novo's Wegovy (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat

2 reports from 2 outlets in 1 language · first reported 2026-10-01 10:58 UTC · updated 2026-10-01 11:11 UTC · JSON

Reports

1. Novo Nordisk A/S: Novo's Wegovy (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fatfinanznachrichten.de · en · 2026-10-01 11:11 UTC
2. Novo's Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat - EASD2026manilatimes.net · en · 2026-10-01 10:58 UTC